-
Acquisition of 588,235 shares at $17.00 per share, representing a total transaction value of ~$10.0 million as of January 9, 2026.
-
This purchase represented 46.49% of Srinivas Akkaraju’s previously disclosed indirect holdings.
-
All shares are held indirectly through Samsara Opportunity Fund, LP, and no direct holdings are reported following the transaction.
-
The transaction follows a series of recent purchases, rapidly increasing exposure against the backdrop of strong stock appreciation in one year (+206.29% as of January 16, 2026).
-
These 10 stocks could generate the next wave of millionaires ›
Srinivas Akkaraju, director of aluminum (NASDAQ: ALMS)executed an open market purchase of 588,235 shares for total consideration of ~$10.0 million on January 9, 2026, according to the SEC Form 4 filing.
|
Metric |
Worth |
|---|---|
|
Shares traded |
588,235 |
|
Transaction value |
$9,999,995.00 |
|
Post-transaction actions (direct) |
0 |
|
Post-transaction actions (indirect) |
1,853,488 |
|
Post-transaction value (direct ownership) |
$0.00 |
Transaction value based on SEC Form 4 reported price ($17.00).
-
How significant is this transaction in relation to Srinivas Akkaraju’s historical trade in Alumis?
This purchase is among the largest on record by this insider, with the 588,235 shares purchased exceeding the historical average trade size of ~186,000 shares and increasing cumulative indirect holdings by nearly 47% in a single event. -
What is the ownership structure of these shares?
All shares in this transaction are held indirectly through Samsara Opportunity Fund, LP, as detailed in the footnotes to the SEC filing, with Srinivas Akkaraju exercising voting and investment power through the fund’s general partner. -
How does the trading price compare to recent market levels?
The acquisition was executed at $17.00 per share, a notable discount to the January 9, 2026 market open and close of $18.50 and $19.56, and further below the January 16, 2026 price of $23.86, reflecting a favorable entry relative to subsequent price action. -
What does this transaction indicate regarding capacity and cadence?
The significant purchase follows a series of incremental builds over the previous two months, suggesting the insider is rapidly gaining exposure as available capacity allows and against the backdrop of strong stock appreciation over the past year.
|
Metric |
Worth |
|---|---|
|
Price (at market close 9/1/26) |
$17.00 |
|
Market capitalization |
$2.49 billion |
|
Revenue (TTM) |
$22.12 million |
|
1 year price change |
206.29% |
*1 year price change calculated using January 9, 2026 as the reference date.
-
It develops clinical-stage biopharmaceutical products targeting autoimmune and neuroinflammatory diseases, including ESK-001 and A-005, focused on allosteric inhibition of TYK2.
-
It operates a research-driven model, generating revenue through the development and potential commercialization of novel therapies for high-need indications.
-
It is aimed at healthcare providers, specialists and biopharmaceutical partners addressing autoimmune and neurodegenerative conditions.